secwatch / observer
8-K filed November 22, 2021, 6:59 PM ET ticker IVVD CIK 0001832038
leadership confidence high sentiment positive materiality 0.50

Adagio adds Jill Andersen as CLO, Redonda Miller and Ellen Marram to board

Invivyd, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ellen Marram

director
IVVD · Invivyd, Inc.
Effective
2021-11-19
Filed
November 22, 2021, 6:59 PM ET
On November 19, 2021, the board of directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Ms. Ellen Marram and Dr. Redonda Miller to serve as directors of the Company.
Appointed

Redonda Miller

director
IVVD · Invivyd, Inc.
Effective
2021-11-19
Filed
November 22, 2021, 6:59 PM ET
On November 19, 2021, the board of directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Ms. Ellen Marram and Dr. Redonda Miller to serve as directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ellen Marram was appointed as director at Invivyd, Inc..

Action
appointed
Role
director
Exact text from the filing
On November 19, 2021, the board of directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Ms. Ellen Marram and Dr. Redonda Miller to serve as directors of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Redonda Miller was appointed as director at Invivyd, Inc..

Action
appointed
Role
director
Exact text from the filing
On November 19, 2021, the board of directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Ms. Ellen Marram and Dr. Redonda Miller to serve as directors of the Company.
View on SEC.gov

Invivyd, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-21-336946
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.